linjc16/ctgov huggingface dataset:
Retrospective Cohort Study of the Physiotherapy in Critically Ill Covid Patients

Study Overview
=================
Brief Summary
-----------------
Retrospective cohort study that will include patients from the ICU of the Hospital de la Santa Creu i Sant Pau in Barcelona during the period between March 11 and May 13, 2020. The cohorts are made up of two groups of patients admitted for severe COVID during the first wave, according to whether or not they received physiotherapy and the possible impact of physiotherapy on the days of mechanical ventilation in the two study groups will be studied.

Official Title
-----------------
Retrospective Cohort Study of the Physiotherapy Procedure in Critically Ill Patients Diagnosed With COVID-19 During the First Wave

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with COVID-19 in critical condition Adults >18 years Admission to the ICU from March 11 to May 13, 2020 Exclusion Criteria: Patients readmitted on 2 occasions during the study period, the second will be omitted income.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Days of mechanical ventilation | To evaluate the effectiveness of early physiotherapy in critically ill patients with COVID-19 admitted to the ICU in terms of reducing days of mechanical ventilation | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| days of stay | Evaluate the days of stay in the ICU | 2 months | 
| Assess morbidity and mortality. | Assess morbidity and mortality. | 2 months | 
| Assess the comorbidities of patients admitted for COVID-19 in critical condition | Assess the comorbidities of patients admitted for COVID-19 in critical condition | 2 months | 
| PNS lesion in prono position | To know if there is a greater risk of suffering a PNS lesion the more rounds of pronation | 2 months | 
| Assess the comorbidities of patients admitted for COVID-19 in critical condition | To know if the delay in the prescription of physiotherapy (FST) influences the appearance of PNS lesions. | 2 months | 
| Start of standing in critrically ill | To evaluate the start of standing (BP) in critically ill patients infected with COVID-19 who underwent FST. | 2 months | 
| Workload in physiotherapy | To assess the workload of the cohort of patients who underwent physiotherapy during the first wave of COVID-19. | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
physical therapy, covid, mechanical ventilation
Hypothalamic-pituitary Dysfunction in Diabetes

Study Overview
=================
Brief Summary
-----------------
Type 2 Diabetes mellitus (T2DM) is a chronic disease with a high prevalence and several comorbidities impacting on public health and society. Among the complications of T2DM it has been showed a high prevalence of hypogonadotropic hypogonadism. Even if hypogonadism is associated to a worse metabolic profile and cardiovascular risk, it is discussed whether and when to treat this potentially reversible form associated to diabetes. In fact, the pathogenic mechanism of this condition in diabetic patients is not fully understood, and its clinical correlates, including the prevalence of other possible associated hypothalamic-pituitary axes dysfunctioning, questioned. The aim of the present study is to assess with an observational, cross sectional study on a large series of type 2 diabetic patients, enrolled consecutively: all the suspected etiologies of this complication in one single evaluation (both acquired and genetic congenital predisposition), its clinical correlates and the real prevalence of the disease using the lastly validated criteria for late onset hypogonadotropic hypogonadism.

Official Title
-----------------
Study of the Hypothalamic-pituitary Dysfuntion in Patients With Diabetes Mellitus

Conditions
-----------------
Diabete Mellitus, Hypogonadism, Hypogonadotropic Hypogonadism, Hypergonadotropic Hypogonadism, Central Hypothyroidism

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnostic testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18 and 80 years old males proved diagnosis of T2DM Exclusion Criteria: patients affected with known hypothalamic-pituitary diseases at the enrollment. patients affected with severe systemic diseases, fever, chronic inflammatory disorders with PCR > 10 mg/dL malnutrition with BMI <17 Kg/m2 use of glucocorticoids at the enrollment poor understanding of spoken and written Italian patients affected with known primary diseases of the testes at the enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Enrolled patients with DM<br> | Diagnostic Test: Diagnostic testing<br>* Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Hypogonadism | LH, FSH, Testosterone, Estradiol | baseline | 
| Genetic predisposition | NGS analysis based on the analysis of a customized gene-panel with all known Congenital Hypogonadotropic Hypogonadism genes | baseline |
Reopening Schools Safely and Educating Youth Research- Early Learning Ancillary Study

Study Overview
=================
Brief Summary
-----------------
This is a single arm, pre/post intervention study to a larger trial that will examine the effect of health education with comic books and videos on COVID-19 preventive behaviors (masking, social distancing, testing and vaccine uptake). The participants are students, ages 3-5 years old and their parents.

Detailed Description
-----------------
This is a single arm, pre/post intervention study to a larger trial that will examine the effect of health education with comic books and videos on COVID-19 preventive behaviors (masking, social distancing, testing and vaccine uptake). The participants are students, ages 3-5 years old and their parents. Students will receive the intervention from November 2023 to March 2024.

Official Title
-----------------
Reopening Schools Safely and Educating Youth Research- Early Learning Ancillary Study

Conditions
-----------------
Absenteeism

Intervention / Treatment
-----------------
* Behavioral: Health Education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have a child attending the Early Learning Program in the Yakima School District Must be able to provide informed consent and legal guardian assent either virtually, on the telephone, or in-person. Must have a permanent mailing address available for study staff to mail necessary materials OR a working email address. Must speak English or Spanish. Exclusion Criteria: - Not in Early Learning program in Yakima School District

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>The students in this arm will receive comic books and their parents videos on the benefits of preventive measures of COVID-19 | Behavioral: Health Education<br>* Health education with comic books and videos<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| School absenteeism | How many days students miss due to symptoms of respiratory illness | Up to nine months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-coV-2, School re-opening, Rural Communities, Early Education - pre School, Risk communication
Role of PET/CT in Peritoneal Deposits Assessment

Study Overview
=================
Brief Summary
-----------------
• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits

Detailed Description
-----------------
Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits. we will find its diagnostic role.

Official Title
-----------------
Role of PET/CT in Peritoneal Deposits Assessment

Conditions
-----------------
Peritoneal Metastases

Intervention / Treatment
-----------------
* Device: PET/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions. Exclusion Criteria: • Patients unable to sit calm without movement during imaging. Severely ill patients. Patients unable to sleep in a fixed position for 20 minutes. Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: PET/CT|• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| role of pet/ct in peritoneal deposits assessment | Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions and will do PET/CT for assessment of peritoneal deposits | 2 years |
Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease (HO-MA)

Study Overview
=================
Brief Summary
-----------------
Alzheimer's disease (AD) is the leading cause of dementia in France. It is a multifactorial pathology, combining genetic and environmental risk factors. Homocysteine, a sulfur-containing amino acid belonging to the methionine-monocarbon cycle, has frequently been found at high levels in neurodegenerative diseases, and in AD in particular. It has been shown on human brain sections that the interaction of homocysteine with tau and MAP1, two key AD proteins, was significantly higher in AD patients than in controls, and corresponded to an N-homocysteinylation type interaction. This is a prospective study, the main objective of which is to compare MAP1 N-homocysteinylation levels in fibroblasts from individuals with AD versus disease-free cell lines.

Official Title
-----------------
Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease

Conditions
-----------------
Alzheimer Disease

Intervention / Treatment
-----------------
* Other: skin biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years Age of onset of AD < 75 years Person with AD with positive CSF biomarkers Person who has previously benefited from an analysis of AD genetic characteristics (APP, PSEN1, PSEN2, TREM2, ABCA7, SORL1 genes and ApoE status) and an analysis of monocarbon metabolism genes in the case of biochemical abnormalities by clinical exome, targeted panel or complete exome, and for whom the data set is already available. Exclusion Criteria: Pregnant, parturient or breast-feeding women Minor (not emancipated) Person of legal age (subject to a legal protection measure) Adult unable to give consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: alzheimer's disease patients<br>Alzheimer's disease patients with positive biomarkers who started their disease before age 75 and benefited from genetic research. | Other: skin biopsy<br>* skin biopsy for cell culture and N-homocysteinylation study<br>|
| Other: Control group<br>control cell lines from patients free of alzheimer's disease | Other: skin biopsy<br>* skin biopsy for cell culture and N-homocysteinylation study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MAP1 homocysteinylation level |  | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Homocysteinylation level of tau protein |  | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genetic, Alzheimer Disease, N-homocysteinylation
Collection of Circulating Biomarkers in Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

Official Title
-----------------
Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer

Conditions
-----------------
Pancreas Cancer

Intervention / Treatment
-----------------
* Other: Obtaining blood for analysis of various circulating biomarkers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma The subject must be a patient of the University of Pennsylvania The subject must be able to provide informed consent The subject must be 18 years of age or older Exclusion Criteria: . Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Blood specimens<br>Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma. | Other: Obtaining blood for analysis of various circulating biomarkers<br>* 4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use. |  | Through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response. |  | Through study completion, an average of 1 year | 
| To integrate the data and specimens to permit the most informative clinical-biologic research platform. |  | Through study completion, an average of 1 year |
Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

Study Overview
=================
Brief Summary
-----------------
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. The last three decades of research in head and neck radiation oncology have largely focused on improvements in survival, which have mostly come at the cost of long term toxicity for surviving patients.This is an observational study that is being done to evaluate the long-term efficacy, learn about the toxicity and quality of life that survivors of nasopharyngeal carcinoma may have following treated with reduced volume intensity modulated radiation therapy.

Official Title
-----------------
A Comprehensive Prospective Study on the 10-Year Outcome and Late Toxicity, Quality of Life of Reduced Volume Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma

Conditions
-----------------
Nasopharyngeal Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Received treatment with Reduced Volume Intensity Modulated Radiation Therapy Age 18 or above, upper limit 65 Ability to comply with the protocol Exclusion Criteria: History of recurrent nasopharyngeal disease A history of any physical, psychological or social condition which would impair with the ability of the patient to cooperate in this study Unable to provide consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival is calculated from diagnosis to death from any cause | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Loco-regional failure-free survival | Loco-regional failure-free survival is calculated from diagnosis to the first loco-regional failure | 10 years | 
| Failure-free survival | Failure-free survival rate is calculated from the date of diagnosis to the date of treatment failure or death from any cause, whichever is first | 10 years | 
| Distant failure-free survival | Distant failure-free survival is calculated from diagnosis to the first remote failure | 10 years | 
| Quality of Life Questionnaires QLQ-C30 | Quality of life as measured by QLQ-C30 | 1year | 
| Quality of Life Questionnaires | Quality of life as measured by QLQ H&N35 | 1year | 
| Evaluation of late toxicities | Clinical toxicities will be grade according to RTOG/CTCAE | 1year |
Feeding Intolerance Risk Prediction Model in Patients With Enteral Nutrition Through Nasogastric Tube

Study Overview
=================
Brief Summary
-----------------
To explore the risk factors of enteral feeding intolerance in critically ill patients, build a risk prediction model and verify it, in order to provide reference for early identification and screening of high-risk groups

Detailed Description
-----------------
Based on the previous literature study, the risk factors of enteral feeding intolerance in critically ill patients were obtained, and the general demographic, disease and treatment information of patients were collected. Four machine learning algorithms, namely traditional logistic regression, random forest, support vector machine and naive Bayes, were used to construct risk prediction models, and the optimal model was selected and verified by comparing the model performance

Official Title
-----------------
Feeding Intolerance Risk Prediction Model in Patients With Enteral Nutrition Through Nasogastric Tube

Conditions
-----------------
Enteral Nutrition

Intervention / Treatment
-----------------
* Behavioral: enteral nutrition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The nutritional status of the patient is assessed by the doctor and the need for enteral nutrition is determined;Patients with first nasogastric tube insertion and successful enteral feeding;There was no gastrointestinal discomfort before enteral nutrition;Patients (or family members) authorized to participate in this study and signed informed consent Exclusion Criteria: Previous gastrointestinal disease or gastrointestinal surgery;enteral nutrition through gastrostomy tube or jejunostomy tube;discontinuation or suspension of enteral nutrition for special reasons other than feeding intolerance;Patients with serious lack of clinical data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| enteral nutrition group<br> | Behavioral: enteral nutrition<br>* The nutritional status of the patient is assessed by the physician to determine the need for enteral nutrition<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feeding intolerance | Any symptoms of gastrointestinal adverse reactions are defined as feeding intolerance | Follow-up was considered complete when the patient reached 7 days of enteral nutrition, the patient was transferred from the ICU, or the patient experienced nutritional interruption for other reasons |